(Q40100017)

17 September 2017

title

The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand (English)

1 reference

17 September 2017

0 references

1 reference

Michael V Tatley

1

1 reference

17 September 2017

Desireé L Kunac

2

1 reference

17 September 2017

Anne McNicholas

3

1 reference

17 September 2017

Lifeng Zhou

4

1 reference

17 September 2017

Suzie Ballantyne

5

1 reference

17 September 2017

Janelle Ashton

6

1 reference

17 September 2017

Paul Stehr-Green

7

1 reference

17 September 2017

Yvonne Galloway

8

1 reference

17 September 2017

Stewart Reid

9

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

17 September 2017

1 reference

17 September 2017

volume

26

1 reference

17 September 2017

issue

22

1 reference

17 September 2017

page(s)

2746-2752

1 reference

A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Under-reporting of adverse drug reactions : a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Harmonisation in pharmacovigilance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

Causal or casual? The role of causality assessment in pharmacovigilance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

The Measurement of Observer Agreement for Categorical Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.017

10.1016/J.VACCINE.2008.03.017

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference